$USAQ
QHSLab, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223040470 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $315.0K $336.4K $269.3K
YoY Change 17.67% 24.91% -17.0%
Cost Of Revenue $125.1K $146.9K $143.7K
YoY Change -5.73% 2.21% -14.14%
Gross Profit $189.9K $189.5K $125.6K
YoY Change 40.67% 50.88% -20.04%
Gross Profit Margin 60.29% 56.33% 46.64%
Selling, General & Admin $175.8K $161.3K $262.6K
YoY Change -15.72% -38.57% -20.8%
% of Gross Profit 92.56% 85.11% 209.05%
Research & Development $44.52K $45.42K $48.41K
YoY Change -17.74% -6.17% 146.84%
% of Gross Profit 23.44% 23.97% 38.54%
Depreciation & Amortization $36.65K $36.64K $36.65K
YoY Change 0.03% -0.03% 103.27%
% of Gross Profit 19.3% 19.33% 29.18%
Operating Expenses $238.3K $224.7K $329.0K
YoY Change -15.1% -31.69% -10.88%
Operating Profit -$48.41K -$35.23K -$203.4K
YoY Change -66.77% -82.68% -4.1%
Interest Expense -$38.23K $48.58K $106.7K
YoY Change -45.77% -54.47% -220.35%
% of Operating Profit
Other Income/Expense, Net $0.00 $1.370K
YoY Change
Pretax Income -$86.64K -$82.44K -$310.1K
YoY Change -59.93% -73.42% 3.11%
Income Tax
% Of Pretax Income
Net Earnings -$86.64K -$82.44K -$310.1K
YoY Change -59.93% -73.42% 3.11%
Net Earnings / Revenue -27.5% -24.51% -115.15%
Basic Earnings Per Share -$0.01 -$0.03
Diluted Earnings Per Share -$0.01 -$0.01 -$0.03
COMMON SHARES
Basic Shares Outstanding 9.736M shares 9.316M shares 9.066M shares
Diluted Shares Outstanding 9.316M shares 9.068M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.58K $50.24K $237.9K
YoY Change -71.13% -78.88% -56.21%
Cash & Equivalents $51.58K $50.24K $237.9K
Short-Term Investments
Other Short-Term Assets $7.990K $4.250K $49.34K
YoY Change 9.3% -91.39% 32.21%
Inventory $25.18K $38.95K $97.96K
Prepaid Expenses
Receivables $71.38K $83.55K $58.09K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $156.1K $177.0K $443.3K
YoY Change -45.33% -60.08% -38.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $1.522M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.525M $1.562M $1.709M
YoY Change -8.77% -8.58% -1.49%
TOTAL ASSETS
Total Short-Term Assets $156.1K $177.0K $443.3K
Total Long-Term Assets $1.525M $1.562M $1.709M
Total Assets $1.681M $1.739M $2.152M
YoY Change -14.1% -19.19% -12.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $78.91K $220.2K $150.0K
YoY Change -7.97% 46.83% 71.31%
Accrued Expenses $24.00K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $546.1K $412.8K $297.2K
YoY Change 59.48% 38.88%
Long-Term Debt Due $546.1K $412.8K $297.2K
YoY Change 59.48% 38.88% -61.74%
Total Short-Term Liabilities $2.057M $2.038M $1.657M
YoY Change 20.52% 23.04% 88.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $209.0K
YoY Change -100.0% -100.0% -76.03%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $209.0K
YoY Change -78.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.057M $2.038M $1.657M
Total Long-Term Liabilities $209.0K
Total Liabilities $2.057M $2.038M $1.866M
YoY Change 9.35% 9.26% -0.23%
SHAREHOLDERS EQUITY
Retained Earnings -$3.983M -$3.897M -$3.299M
YoY Change 13.33% 18.13%
Common Stock $974.00 $932.00 $932.00
YoY Change 4.51% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$375.6K -$299.5K $286.2K
YoY Change
Total Liabilities & Shareholders Equity $1.681M $1.739M $2.152M
YoY Change -14.1% -19.19% -12.33%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$86.64K -$82.44K -$310.1K
YoY Change -59.93% -73.42% 3.11%
Depreciation, Depletion And Amortization $36.65K $36.64K $36.65K
YoY Change 0.03% -0.03% 103.27%
Cash From Operating Activities -$135.2K $13.07K -$183.1K
YoY Change 93.71% -107.14% 33.91%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 136.5K -71.67K 323.9K
YoY Change 1193.93% -122.13% -43.9%
NET CHANGE
Cash From Operating Activities -135.2K 13.07K -183.1K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 136.5K -71.67K 323.9K
Net Change In Cash 1.340K -58.60K 140.8K
YoY Change -102.26% -141.63% -64.58%
FREE CASH FLOW
Cash From Operating Activities -$135.2K $13.07K -$183.1K
Capital Expenditures $0.00
Free Cash Flow -$183.1K
YoY Change 95.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000856984
CY2023Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
usd
CY2022Q3 us-gaap Other Income
OtherIncome
usd
us-gaap Other Income
OtherIncome
usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Payments For Software
PaymentsForSoftware
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
USAQ Debt And Accrued Interest Converted To Shares Of Common Stock
DebtAndAccruedInterestConvertedToSharesOfCommonStock
usd
USAQ Warrants Issued In Conjunction With Convertible Note Payable
WarrantsIssuedInConjunctionWithConvertibleNotePayable
usd
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-19041
dei Entity Registrant Name
EntityRegistrantName
QHSLab, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-1104301
dei Entity Address Address Line1
EntityAddressAddressLine1
901 Northpoint Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 302
dei Entity Address Address Line3
EntityAddressAddressLine3
West Palm
dei Entity Address City Or Town
EntityAddressCityOrTown
Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33407
dei City Area Code
CityAreaCode
(929)
dei Local Phone Number
LocalPhoneNumber
379-6503
dei Security12g Title
Security12gTitle
Common Stock, $0.0001 Par Value
dei Trading Symbol
TradingSymbol
USAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9735508 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50240 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178694 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
83550 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
47734 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
38954 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
51840 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4246 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7310 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
176990 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
285578 usd
CY2023Q3 us-gaap Capitalized Software Development Costs For Software Sold To Customers
CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers
111695 usd
CY2022Q4 us-gaap Capitalized Software Development Costs For Software Sold To Customers
CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers
167543 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1450248 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1504332 usd
CY2023Q3 us-gaap Assets
Assets
1738933 usd
CY2022Q4 us-gaap Assets
Assets
1957453 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
220237 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
85743 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
159395 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
116774 usd
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
412781 usd
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
342391 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1246000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1161918 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2038413 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1706826 usd
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
174382 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
174382 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2038413 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1881208 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9315508 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9315508 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9315508 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9315508 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
932 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
932 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3595837 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3589837 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3896621 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3514896 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-299480 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76245 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1738933 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1957453 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
336407 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
269323 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1093974 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
975469 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
146897 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
143716 usd
us-gaap Cost Of Revenue
CostOfRevenue
490294 usd
us-gaap Cost Of Revenue
CostOfRevenue
490965 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
189510 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
125607 usd
us-gaap Gross Profit
GrossProfit
603680 usd
us-gaap Gross Profit
GrossProfit
484504 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
114019 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
154620 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
366055 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
387687 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47277 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
107965 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
205799 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
321573 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45419 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48405 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
169489 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
135998 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18028 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18028 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
54084 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
54084 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
224743 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
329018 usd
us-gaap Operating Expenses
OperatingExpenses
795427 usd
us-gaap Operating Expenses
OperatingExpenses
899342 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-35233 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-203411 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-191747 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-414838 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
48581 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
106704 usd
us-gaap Interest Expense
InterestExpense
192268 usd
us-gaap Interest Expense
InterestExpense
362946 usd
CY2023Q3 us-gaap Other Income
OtherIncome
1371 usd
us-gaap Other Income
OtherIncome
2290 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2020 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-82443 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-310115 usd
us-gaap Net Income Loss
NetIncomeLoss
-381725 usd
us-gaap Net Income Loss
NetIncomeLoss
-779804 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9315508 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9315508 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9068225 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9068225 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9315508 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9315508 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8889836 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8889836 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76245 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-192555 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-110310 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-106727 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-217037 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-82443 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-299480 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
824066 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48921 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3484 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
27925 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2020 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8920 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-190304 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
676111 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3484 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8921 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-279385 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
409131 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
409131 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
50000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
81183 usd
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
50000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-310115 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
286199 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
286199 usd
us-gaap Net Income Loss
NetIncomeLoss
-381725 usd
us-gaap Net Income Loss
NetIncomeLoss
-779804 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5992 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9173 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
109932 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
91315 usd
USAQ Amortization Of Debt And Warrant Issuance Costs
AmortizationOfDebtAndWarrantIssuanceCosts
84082 usd
USAQ Amortization Of Debt And Warrant Issuance Costs
AmortizationOfDebtAndWarrantIssuanceCosts
267889 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23842 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
6968 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2020 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
41808 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3207 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-12886 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
32219 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3064 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26622 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
134494 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
129625 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
42621 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
23401 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24462 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-281205 usd
us-gaap Payments For Software
PaymentsForSoftware
37119 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37119 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
400000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
162000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
128500 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
265992 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
279097 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
30000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-103992 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
269403 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-128454 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178694 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
286855 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50240 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
237934 usd
us-gaap Interest Paid Net
InterestPaidNet
36930 usd
us-gaap Interest Paid Net
InterestPaidNet
55939 usd
USAQ Debt And Accrued Interest Converted To Shares Of Common Stock
DebtAndAccruedInterestConvertedToSharesOfCommonStock
77925 usd
USAQ Warrants Issued In Conjunction With Convertible Note Payable
WarrantsIssuedInConjunctionWithConvertibleNotePayable
81183 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80B_eus-gaap--NatureOfOperations_zSPKp8fb5yZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. <span id="xdx_824_zvHd30A2kHxl">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QHSLab, Inc. (the “Company” or the “Registrant”) was incorporated in Delaware on September 1, 1983. In 2019, the Company became engaged in value-based healthcare, informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada. On April 19, 2022, the Company changed its name to QHSLab, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a medical device technology and software-as-a-service (“SaaS”) company focused on enabling primary care physicians (“PCP’s”) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zWBUDjzqvzYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zfPXb4zJZzge">Use of Estimates</span>:</i> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
223390 usd
CY2023Q3 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
18616 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
55848 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
37231 usd
CY2022 us-gaap Capitalized Computer Software Impairments1
CapitalizedComputerSoftwareImpairments1
0 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45419 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48405 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
169489 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
135998 usd
CY2023Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
3896621 usd
USAQ Net Operating Losses Carryforwards Expire Date
NetOperatingLossesCarryforwardsExpireDate
begin to expire in 2027
CY2023Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
97772 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
55964 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
14222 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8230 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
83550 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
47734 usd
CY2023Q3 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
223390 usd
CY2022Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
223390 usd
CY2023Q3 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
111695 usd
CY2022Q4 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
55847 usd
CY2023Q3 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
111695 usd
CY2022Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
167543 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1612500 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1612500 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
162252 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
108168 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1450248 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1504332 usd
CY2023Q3 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
111695 usd
CY2022Q4 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
55847 usd
CY2023Q3 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
18616 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
55848 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
37231 usd
CY2022 us-gaap Capitalized Computer Software Impairments1
CapitalizedComputerSoftwareImpairments1
0 usd
CY2021Q2 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
1612500 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18028 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18028 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
54084 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
54084 usd
CY2023Q3 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
386735 usd
CY2022Q4 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
426451 usd
CY2023Q2 us-gaap Proceeds From Loans
ProceedsFromLoans
162000 usd
CY2023Q2 us-gaap Payments For Loans
PaymentsForLoans
20538 usd
CY2023Q2 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
October 2024
CY2023Q3 us-gaap Loans Payable
LoansPayable
40821 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1246000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1246000 usd
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
84082 usd
CY2023Q3 USAQ Convertible Notes Payable Debt Discount And Issuance Costs
ConvertibleNotesPayableDebtDiscountAndIssuanceCosts
1246000 usd
CY2022Q4 USAQ Convertible Notes Payable Debt Discount And Issuance Costs
ConvertibleNotesPayableDebtDiscountAndIssuanceCosts
1161918 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1246000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1161918 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.25
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2594854 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2676647 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2594854 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2676647 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2594854 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2676647 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2594854 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2676647 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23842 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1100000 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
81793 shares

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
usaq-20230930_cal.xml Edgar Link unprocessable
0001493152-23-040470-index-headers.html Edgar Link pending
0001493152-23-040470-index.html Edgar Link pending
0001493152-23-040470.txt Edgar Link pending
0001493152-23-040470-xbrl.zip Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usaq-20230930.xsd Edgar Link pending
usaq-20230930_def.xml Edgar Link unprocessable
usaq-20230930_lab.xml Edgar Link unprocessable
usaq-20230930_pre.xml Edgar Link unprocessable